Autopsy report · NCT00428116

Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya

“DSMB recommended termination because TI was safe but not durable.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 8 months before it started.
• Ran for about 7 years 3 months before it stopped.
• 140 participants enrolled.
• Results were posted on the registry 8 months after it ended.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

University of Washington

Sponsor type

University, hospital or other

Conditions

HIV Infections

Interventions

HAART

Participants

140

Trials that died the same way

• A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung
  “The Data Safety Monitoring Board (DSMB) recommended study termination for slow accrual and futility.” (72% match in meaning)
• Testing Pharmacological Therapies for Pregnant Smokers
  “was terminated due to meeting a priori stopping rule set by DSMB” (63% match in meaning)
• Daily Isoniazid to Prevent Tuberculosis in Infants Born to Mothers With HIV
  “Data Safety Monitoring Board (DSMB) recommended stopping study due to futility” (62% match in meaning)
• A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy
  “Upon recommendation of DSMB” (62% match in meaning)
• Helping HIV Infected Patients in South Africa Adhere to Drug Regimens
  “DSMB stopped trial for futility” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.